Revivo Therapeutics is addressing major unmet medical needs with a with a new class of small orally active molecules for the treatment of

• Traumatic Brain Injury

• Mild Cognitive Impairment

  Our lead compound has been evaluated in Phase 1 studies and is poised for Phase 2 Evaluations in target populations.